Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
äŒæ¥ã³ãŒãFLGT
äŒç€ŸåFulgent Genetics Inc
äžå Žæ¥Sep 28, 2016
æé«çµå¶è²¬ä»»è
ãCEOãHsieh (Ming)
åŸæ¥å¡æ°1313
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Sep 28
æ¬ç€Ÿæåšå°4399 Santa Anita Ave
éœåžEL MONTE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·91731
é»è©±çªå·16263500537
ãŠã§ããµã€ãhttps://www.fulgentgenetics.com/
äŒæ¥ã³ãŒãFLGT
äžå Žæ¥Sep 28, 2016
æé«çµå¶è²¬ä»»è
ãCEOãHsieh (Ming)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã